GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER plus Breast Cancer

Breast cancer remains a leading cause of cancer death in women, representing a significant unmet medical need. Here, we disclose our discovery efforts culminating in a clinical candidate, 35 (GDC-9545 or giredestrant). 35 is an efficient and potent selective estrogen receptor degrader (SERD) and a full antagonist, which translates into better antiproliferation activity than known SERDs (1, 6, 7, and 9) across multiple cell lines. Fine-tuning the physiochemical properties enabled once daily oral dosing of 35 in preclinical species and humans. 35 exhibits low drug-drug interaction liability and demonstrates excellent in vitro and in vivo safety profiles. At low doses, 35 induces tumor regressions either as a single agent or in combination with a CDK4/6 inhibitor in an ESR1Y537S mutant PDX or a wild-type ER alpha tumor model. Currently, 35 is being evaluated in Phase III clinical trials.

Automated summary

The discovery of clinical candidate 35 (GDC-9545 or giredestrant) as an efficient and potent selective estrogen receptor degrader (SERD) and full antagonist has shown promising results in preclinical studies, demonstrating low drug-drug interaction liability and excellent safety profiles. This compound is currently undergoing Phase III clinical trials for the treatment of breast cancer.